Pacific Shuanglin Bio-pharmacy Hits Day Low Amid Price Pressure at CNY 13.57

Pacific Shuanglin Bio-pharmacy Co., Ltd. experienced a notable decline today, with the stock dropping by 3.12% and reaching an intraday low of CNY 13.57. This performance stands in contrast to the China Shanghai Composite, which fell by 1.24% on the same day. Over the past week, Pacific Shuanglin has seen a decrease of 5.01%, while its one-year performance reflects a significant decline of 19.57%, compared to the market's positive return of 16.08%. The company's financial metrics indicate ongoing challenges, with net sales reported at CNY 631.66 million, marking a decrease of 16.23%. Additionally, the operating cash flow has reached its lowest point at CNY 78.7 million, and the return on capital employed (ROCE) stands at a modest 7.06%. Over the last three years, the stock has underperformed the market, with a staggering decline of 37.63%. As a large-cap player in the pharmaceuticals and biotechnology sector, Pacific Shuanglin's current market capitalization is CNY 12,690 million, and it maintains a price-to-earnings ratio of 24.00, alongside a dividend yield of 1.76%.